It’s not even close to fold...stop with the dribble. They could RS, they could settle for an equity partner, they could do about a ton of different scenarios and keep moving.
Absssi is not a blue sky market. There many antibiotics and the return is much smaller based on trials needed. OM is a completely different arena. The only comparison would be IF there was a world crisis that dapto and others do not work anymore. Then B absssi is as valuable as b-OM. IMO.
Call Art and ask him to discuss how important today is and this exact moment in time is for this indication. B-OM really could be the leader in a growing indication.
BP knows this as well. I believe we see a deal ASAP once all the boxes are checked.
News 
Market Data 
Discover 
